Bienville Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bienville Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,421	Closed	-$448K	–	224
2019 Q2	$448K	Hold	3,421	–	–	0.05%	92
2019 Q1	$462K	Hold	3,421	–	–	0.05%	83
2018 Q4	$333K	Buy	3,421 +1,421	+71%	+$168K	0.06%	100
2018 Q3	$278K	Hold	2,000	–	–	0.02%	88
2018 Q2	$248K	Sell	2,000 -39	-2%	-$4.56K	0.02%	108
2018 Q1	$227K	Sell	2,039 -1,470	-42%	-$176K	0.04%	116
2017 Q4	$420K	Buy	3,509 +75	+2%	+$9.13K	0.07%	111
2017 Q3	$482K	Buy	3,434 +1	+0%	+$136	0.08%	82
2017 Q2	$418K	Sell	3,433 -667	-16%	-$77.6K	0.12%	84
2017 Q1	$497K	Buy	4,100 +700	+21%	+$90.2K	0.12%	71
2016 Q4	$416K	Hold	3,400	–	–	0.09%	76
2016 Q3	$417K	Hold	3,400	–	–	0.11%	75
2016 Q2	$397K	Buy	+3,400	New	+$482K	0.11%	65
2015 Q1	–	Sell	-3,800	Closed	-$703K	–	96
2014 Q4	$703K	Buy	+3,800	New	+$704K	0.58%	30

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bienville Capital Management's ALXN Position: Q3 2019 in Review

Bienville Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 3,421 shares — an estimated $448K sold.

Bienville Capital Management first reported a position in ALXN in Q4 2014 and held it in 14 quarters. The position peaked at $703K in Q4 2014. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Bienville Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Bienville Capital Management sold 3,421 Alexion Pharmaceuticals shares in Q3 2019, an estimated $448K.
Bienville Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 14 quarters.
Bienville Capital Management's Alexion Pharmaceuticals position peaked at $703K in Q4 2014.
647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Bienville Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.